StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

<< Previous

Bullboard Posts

Next >>

Post by Nailbiter2on Dec 29, 2024 4:30pm

175 Views

Post# 36380146

C'mon Jimmy T

The Company is diligently continuing its efforts to have sufficient funds to fully pay the auditors. It anticipates having them paid by December 31st, 2024. An application has been made to the OSC for a partial revocation of the FFCTO. The partial revocation would be needed to allow for a possible equity transaction with the specific purpose of filing the 2023 year end financials and associated documents, and then applying for a full revocation of the FFCTO. Funding could come in the form of an equity transaction, or as a debt transaction. The Company will update the market as required and once agreements have been concluded.